October 11th 2021
An increased understanding of driver gene alterations in advanced non–small cell lung cancer (NSCLC) has led to the development of targeted therapies that offer improved patient outcomes. Ben Levy, MD; Mark A. Socinski, MD; and Stephen Liu, MD, share their thoughts on the emerging treatment landscape and remaining unmet needs.
September 20th 2021
Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.
A panel of experts debate the cost of innovation vs disruptive pricing of therapy.
September 13th 2021
Jack West, MD, and Gilberto Lopes, MD, share their thoughts on mitigating strategies of therapy associated with financial toxicity.
Mark Socinski, MD, and Jack West, MD, review the GEMSTONE-301 and GEMSTONE-302 trials.
September 7th 2021
A panel of experts in cancer treatment review the need for PD-1/PD-L1 testing for immunotherapy.
Gilberto Lopes, MD, Jack West, MD, and Mark Socinski, MD, provide their insight on the pharmacoeconomic considerations for immunotherapy.
August 30th 2021
Experts in cancer care management review PD-1/PD-L1 immunotherapy for patients with NSCLC and GI cancers.
A panel of experts discuss treatment options based on efficacy and out-of-pocket cost for patients.
May 26th 2021
Mark A. Socinski, MD, discusses the utility of circulating tumor DNA testing in lung cancer.
May 18th 2021
Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.
February 6th 2021
Mark A. Socinski, MD, discusses the role of immunotherapy in PD-L1–negative lung cancer.
March 31st 2020
Mark A. Socinski, MD, discusses his recommendations for conducting molecular testing in lung cancer.
April 16th 2019
Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses new applications for immunotherapy in the treatment of patients with non–small cell lung cancer.
March 26th 2019
Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses mechanisms of resistance in the treatment of patients with lung cancer.
February 22nd 2019
Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses the current state of treatment for patients with non–small cell lung cancer.
January 30th 2019
Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses combination versus single-agent immunotherapy in patients with squamous non–small cell lung cancer.
April 26th 2017
Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses potential improvements to immunotherapy regimens for patients with lung cancer.
March 6th 2017
Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses the type of milestone that immunotherapy has had on the field of lung cancer.
February 7th 2017
Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses recent setbacks in immunotherapy combinations in non–small cell lung cancer (NSCLC).